StockUS listing USGIKLYPINKHealthcareDeep Value

Grifols SA ADR(GIKLY) Stock Analysis | Healthcare

USD --+0.00%
Reward57Moderate
Risk59Medium-High
75%Data
Thin 5% profit margin
USD —+0.00 (+0.00%) Previous close · PINK
Market cap 8.78Bn
Reward Ratingⓘ57 Moderate reward assessment · 75% data coverage
Top 50% of stocksView factors
Risk Ratingⓘ59 Medium-High risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on GIKLY to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Grifols SA ADR?

operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally.

AI Brief Pro

The brief on Grifols SA ADR

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Grifols SA ADR?

operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factor VIII/von Willebrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 8.78B, and a P/E ratio of 20.2x.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Adequate profitability with some margin variability in recent periods.
Risk
Moderate volatility with meaningful macro and earnings sensitivity.
Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: Moderate (57)

Similar stocks to compare

A short list of Drug Manufacturers - General names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryDrug Manufacturers - General
P/E Ratio20.1563
Beta1.214
Insider Activity
12M windowNo data
No insider activity data available for this ticker.